AstraZeneca and Galderma link up for collaboration

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Switzerland’s Galderma Pharma have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis which significantly affect the health and quality of life for millions of people worldwide. Under the terms of the five-year deal, financial terms of which were not revealed, Galderma – a joint venture of L’Oreal and Nestle – will have exclusive access to a number of compounds from across AstraZeneca’s portfolio to develop in dermatological indications.


Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top